Lifecore Biomedical Q1 Earnings Call Highlights

Lifecore Biomedical Q1 Earnings Call Highlights Lifecore Biomedical logo MarketBeat May 6, 2026 7 min read LFCR Key Points Management added three commercial site transfer programs in Q1 — including a U.S. aesthetics transfer and two CDMO agreements (one ophthalmic expansion) — and expects these to generate commercial revenue around 2028, each as mid‑seven‑figure opportunities. Q1 revenue fell 34% to $23.2M with a net loss of $15.0M and adjusted EBITDA of $1.0M, but the company cut SG&A/R&D (cumulative reductions ~$8M since late‑2024) and finished the quarter with about $38M in liquidity and positive operating cash flow. Management reaffirmed full‑year 2026 guidance (revenue $120–125M, adjusted EBITDA $20.5–25M) and reiterated long‑term targets of roughly a 12% revenue CAGR and >25% EBITDA margin by end of 2029.

Interested in Lifecore Biomedical, Inc.? Here are five stocks we like better. Lifecore Biomedical (NASDAQ:LFCR) executives highlighted new commercial site transfer wins, continued cost reductions, and improving liquidity during the company's first-quarter 2026 earnings call, while acknowledging a year-over-year revenue decline tied to previously discussed headwinds.

Management reiterates long-term targets and reaffirms 2026 outlook President and CEO Paul Josephs said the company continued executing on "each of the three pillars" of its growth strategy: expanding existing commercial business, advancing development programs toward commercialization, and adding new programs through business development. Josephs said the company believes consistent execution supports its longer-term goal of a 12% revenue compound annual growth rate and EBITDA margins above 25% by the end of 2029. → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries Chief Financial Officer Ryan Lake reaffirmed full-year 2026 guidance, calling out the company's expectations for: Total revenue: $120 million to $125 million Net loss: $35.4 million to $30.9 million Adjusted EBITDA: $20.5 million to $25 million Three new commercial site transfer programs added in the quarter Josephs emphasized business development momentum in early 2026, noting that Lifecore signed three new commercial site transfer programs in the first quarter. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches In March, the company announced a manufacturing services agreement with a new aesthetics customer for the commercial site transfer of a marketed, approved product currently manufactured outside the U.S. Josephs said the customer's goal is to establish U.S.-based manufacturing for products sold domestically, adding that Lifecore believes the product "may generate commercial revenue in 2028." Story Continues The company also signed two CDMO manufacturing services agreements with an existing U.S. biopharmaceutical customer.

One agreement covers a commercial site transfer for a currently marketed product produced by another CDMO, with Lifecore performing technical transfer services to support regulatory approval at its site before commercial manufacturing begins. The second agreement expands an existing relationship for a commercial ophthalmic product Lifecore already manufactures in one delivery format; the company will now manufacture it in a second delivery system currently made in Europe. Josephs said the second delivery system is expected to be additive to existing commercial revenue for that product. → Tyson Foods' Total Returns: Tasty Treats for Income Investors?

During the Q&A, management said the three commercial tech transfers are expected to generate commercial revenue in the 2028 timeframe, describing them as "mid 7-figure opportunities" for Lifecore. Development pipeline updates, including Indomo expansion and late-stage programs On development programs, Josephs highlighted an expanded relationship with Indomo, a clinical-stage therapeutics company. He said Lifecore signed a second agreement in January after previously being selected for formulation and process optimization work supporting Indomo's DT-001 program.

Under the new agreement, Lifecore will produce and supply clinical batches of DT-001 for studies intended to prepare the product to advance into Phase II clinical trials in 2026. Josephs said Lifecore's late-stage development pipeline includes 13 late-stage programs, and that the three programs announced during the quarter were added to that group. He also said five late-stage programs are commercial site transfers, which he characterized as having existing market demand and being "significantly de-risked" compared with development programs because they do not require additional clinical trials and instead require qualification at Lifecore.